ListarFHEFD - Artículos por tema "Depression"
Mostrando ítems 1-13 de 13
-
A Role for Galanin N-Terminal Fragment (1–15) in Anxiety- and Depression-Related Behaviors in Rats.
Millón-Peñuela, Carmelo
; Flores-Burgess, Antonio; Narváez-Peláez, Manuel; Borroto Escuela, Dasiel Óscar; Santín-Núñez, Luis Javier; Parrado-Romero, Concepción; Narvaez, Jose Angel; Fuxe, Kjell; Díaz-Cabiale, Zaida[et al.] (Oxford Academic, 2015-02-16)
Galanin (GAL) plays a role in mood regulation. In this study we analyzed the action of the active N-terminal fragment [GAL(1–15)] in anxiety- and depression-related behavioral tests in rats. Methods: The effect of ... -
Existence of FGFR1-5-HT1AR heteroreceptor complexes in hippocampal astrocytes. Putative link to 5-HT and FGF2 modulation of hippocampal gamma oscillations
Narváez-Peláez, Manuel; Andrade-Talavera, Yunieski; Valladolid-Acebes, Ismael; Fredriksson, Magnus; Siegele, Pia; Hernandez-Sosa, Alejandro; Fisahn, André; Fuxe, Kjell; Borroto-Escuela, Dasiel O.[et al.] (Elsevier, 2020-06-15)
The majority of the fibroblast growth factor receptor 1-serotonin 1 A receptor (FGFR1-5-HT1AR) heterocomplexes in the hippocampus appeared to be located mainly in the neuronal networks and a relevant target for antidepressant ... -
Galanin (1-15) potentiates the antidepres-sant-like effects induced by Escitalopram in a rat model of depression
García-Durán, Laura; Flores-Burgess, Antonio; Cantero-García, Noelia; Puigcerver-Martínez, Araceli; Narváez-Bueno, José Ángel; Fuxe, Kjell; Santín-Núñez, Luis Javier; Millón-Peñuela, Carmelo; Díaz-Cabiale, Zaida[et al.] (2021-10-07)
Selective 5-HT reuptake inhibitor antidepressants (SSRIs) are the first choice in major depressive disorder (MDD), but 50% of affected patients do not show improvement. Galanin(1-15) [GAL(1-15)] enhanced Fluoxetine ... -
Galanin (1–15) enhances the antidepressant effects of the 5-HT1A receptor agonist 8-OH-DPAT: involvement of the raphe-hippocampal 5-HT neuron system
Millón-Peñuela, Carmelo; Flores-Burgess, Antonio; Narváez-Peláez, Manuel; Borroto Escuela, Dasiel Óscar; Santín-Núñez, Luis Javier; Gago-Calderón, Belén; Narváez-Bueno, José Ángel; Fuxe, Kjell; Díaz-Cabiale, Zaida[et al.] (Springer Nature, 2016-01-20)
Galanin N-terminal fragment (1–15) [GAL(1–15)] is associated with depression-related and anxiogenic-like effects in rats. In this study, we analyzed the ability of GAL(1–15) to modulate 5-HT1A receptors (5-HT1AR), a key ... -
Galanin and neuropeptide Y interactions elicit antidepressant activity linked to neuronal precursor cells of the dentate gyrus in the ventral hippocampus
Borroto-Escuela, Dasiel O.; Pita-Rodríguez, Mariana; Fores-Pons, Ramón; Barbancho-Fernández, Miguel Ángel; Fuxe, Kjell; Narváez-Peláez, Manuel[et al.] (Wiley, 2021-02-21)
A need for new antidepressants is necessary since traditional antidepressants have several flaws. Neuropeptide Y(NPY) Y1 receptor (NPYY1R) and galanin (GAL) receptor 2 (GALR2) interact in several regions of the limbic ... -
Galanin receptor 2-neuropeptide Y Y1 receptor interactions in the dentate gyrus are related with antidepressant-like effects.
Narváez-Peláez, Manuel; Borroto Escuela, Dasiel Óscar; Millón-Peñuela, Carmelo; Gago-Calderón, Belén; Flores-Burgess, Antonio; Santín-Núñez, Luis Javier; Fuxe, Kjell; Narváez-Bueno, José Ángel; Díaz-Cabiale, Zaida[et al.] (Springer Nature, 2015-12-14)
Galanin (GAL) and the NPYY1 agonist play a role in mood regulation and both neuropeptides interact in several central functions. The present study examined the interaction between Galanin receptor 2 (GALR2) and Neuropeptide ... -
GALR2 and Y1R agonists intranasal infusion enhanced adultventral hippocampal neurogenesis and antidepressant‐likeeffects involving BDNF actions
Álvarez-Contino, José Erik; Díaz-Sánchez, Estela; Mirchandani-Duque, Marina; Sánchez-Pérez, José Andrés; Barbancho-Fernández, Miguel Ángel; López-Salas, Alexander; García-Casares, Natalia; Fuxe, Kjell; Borroto-Escuela, Dasiel O.; Narváez-Peláez, Manuel[et al.] (Wiley, 2023)
Dysregulation of adult hippocampal neurogenesis is linked to major depressive disorder(MDD), with more than 300 million people diagnosed and worsened by the COVID‐19pandemic. Accumulating evidence for neuropeptideY (NPY) ...